Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 1, 2000, Pages 89-111

  Wójcik, Cezary ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Alzheimer's disease; antigen presentation; cancer; drug discovery; hypertension; inflammation; malaria; neurodegeneration; proteasome; proteolysis; therapy; ubiquitin

Indexed keywords

EID: 0002059613     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.1.89     Document Type: Review

References (211)

1. ROCK KL, GRAMM C, ROTHSTEIN L et al.: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 78:761-771. (Pubitemid 24294452)
2. LEE DH, TANAKA K, TAMURA T, CHUNG CH, ICHIHARA A: PRS3 encoding an essential subunit of yeast proteasomes homologous to mammalian proteasome subunit C5. Biochem. Biophys. Res. Comm. (1992) 182:452-460.
3. OHBA M: A 70-kDa heat shock cognate protein suppresses the defects caused by a proteasome mutation in Saccharomyces cerevisiae. FEBS Lett. (1994) 351:263-266. (Pubitemid 24277283)
4. WÓJCIK C: Proteasomes in apoptosis-guardians or villains? Cell. Mol. Life Sci. (1999) (In Press).
5. GLAS R, BOGYO M, MCMASTER JS, GACZYNSKA M, PLOEGH HL: A proteolytic system that compensates for loss of proteasome function. Nature (1998) 392:618-622. (Pubitemid 28207721)
6. GEIER E, PFEIFER G, WILM M et al.: A giant protease with potential to substitute for some functions of the proteasome. Science (1999) 283:978-981.
7. NEUFELD EF: Lysosomal storage diseases. Ann. Rev. Biochem. (1991) 60:257-280.
8. SCHWARTZ AL, CIECHANOVER A: The ubiquitinproteasome pathway and pathogenesis of human diseases. Ann. Rev. Med. (1999) 50:57-74. (Pubitemid 29117052)
9. ANDRE P, GROETTRUP M, KLENERMAN P et al.: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA (1998) 95:13120-13124. (Pubitemid 28509534)
10. RAO S, PORTER DC, CHEN X et al.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA (1999) 96:7797-7802. (Pubitemid 29328361)
11. CIECHANOVER A, HOD Y, HERSHKO A: A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem. Biophys. Res. Commun. (1978) 81:1100-1105. (Pubitemid 8331462)
12. OZKAYNAK E, FINLEY D, VARSHAVSKY A: The yeast ubiquitin gene: head-to-tail repeats encoding a polyubiquitin precursor protein. Nature (1984) 312:663-666. (Pubitemid 15218343)
13. HERSHKOA, CIECHANOVER A: The ubiquitin system. Ann. Rev. Biochem. (1998) 67:425-479.
14. CIECHANOVER A, BREITSCHOPF K, HATOUM OA, BENGAL E: Degradation of MyoD by the ubiquitin pathway: regulation by specific DNA-binding and identification of a novel site for ubiquitination. Mol. Biol. Rep. (1999) 26:59-64. (Pubitemid 29223252)
15. WU RS, KOHN KW, BONNER WM: Metabolism of ubiquitinated histones. J . Biol. Chem. (1981) 256:5916-5920.
16. STROUS GJ, GOVERS R: The ubiquitin-proteasome system and endocytosis. J. Cell Sci. (1999) 112:1417-1423.
17. FINLEY D, BARTEL B, VARSHAVSKY A: The tails of ubiquitin precursors are ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis. Nature (1989) 338:394-401. (Pubitemid 19089321)
18. ANDREA AD, PELLMAN D: Deubiquitinating enzymes: a new class of biological regulators. Crit. Rev. Biochem. Mol. Biol. (1998) 33:337-352. (Pubitemid 28512486)
19. WILKINSON KD: Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J. (1997) 11:1245-1256. (Pubitemid 27527888)
20. RUBIN DM, FINLEY D: Proteolysis. The proteasome: a protein-degrading organelle? Curr. Biol. (1995) 5:854-858.
21. HENDIL KB: The 19 S multicatalytic 'prosome' proteinase is a constitutive enzyme in HeLa cells. Biochem. Intl. (1988) 17:471-477.
22. BOCHTLER M, DITZEL L, GROLL M, HARTMANN C, HUBER R: The proteasome. Ann. Rev. Biophys. Biomol. Struct. (1999) 28:295-317. (Pubitemid 29319261)
23. DEMARTINO GN, SLAUGHTER CA: The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. (1999) 274: 22123-22126.
24. GROLL M, DITZEL L, LOWE J et al.: Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature (1997) 386:463-471. (Pubitemid 27164066)
25. WILK S, ORLOWSKI M: Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J. Neurochem. (1980) 35:1172-1182. (Pubitemid 11198291)
26. WILK S, ORLOWSKI M: Evidence that pituitary cationsensitive neutral endopeptidase is a multicatalytic protease complex. J. Neurochem. (1983) 40:842-849. (Pubitemid 13146816)
27. PUHLER G, WEINKAUF S, BACHMANN L et al.: Subunit stoichiometry and three-dimensional arrangement in proteasomes from Thermoplasma acidophilum. EMBO J. (1992) 11:1607-1616.
28. LOWE J, STOCK D, JAP B et al.: Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science (1995) 268:533-539.
29. KOPP F, HENDIL KB, DAHLMANN B et al.: Subunit arrangement in the human 20S proteasome. Proc. Natl. Acad. Sci. USA (1997) 94:2939-2944. (Pubitemid 27157243)
30. FRUH K, GOSSEN M, WANG K et al.: Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J. (1994) 13:3236-3244. (Pubitemid 24226938)
31. FRUH K, YANG Y: Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol. (1999) 11:76-81. (Pubitemid 29082341)
32. KLOETZEL PM, SOZA A, STOHWASSER R: The role of the proteasome system and the proteasome activator PA28 complex in the cellular immune response. Biol. Chem. (1999) 380:293-297. (Pubitemid 29145942)
33. DEMARTINO GN, PROSKE RJ, MOOMAW CR et al.: Identification, purification, and characterization of a PA700-dependent activator of the proteasome. J. Biol. Chem. (1996) 271:3112-3118. (Pubitemid 26060528)
34. GLICKMAN MH, RUBIN DM, FRIED VA, FINLEY D: The regulatory particle of the Saccharomyces cerevisiae proteasome. Mol. Cell. Biol. (1998) 18:3149-3162. (Pubitemid 28240488)
35. GLICKMAN MH, RUBIN DM, COUX Oet al.: A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell (1998) 94:615-623. (Pubitemid 28427580)
36. DUBIEL W, PRATT G, FERRELL K, RECHSTEINER M: Purification of an 11 S regulator of the multicatalytic proteinase. J. Biol. Chem. (1992) 267:22369-22377.
37. MA CP, SLAUGHTER CA, DEMARTINO GN: Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem. (1992) 267:10515-10523.
38. TANAHASHI N, YOKOTA K, AHN JY et al.: Molecular properties of the proteasome activator PA28 family proteins and gamma-interferon regulation. Genes Cells (1997) 2:195-211.
39. TOJO T, KABURAKI M, HAYAKAWA T et al.: Precipitating antibody to a soluble nuclear antigen 'Ki' with specificity for systemic lupus erythematosus. Ryumachi (1981) 21(Suppl.):129-134. (Pubitemid 12108903)
40. CHU-PING M, SLAUGHTER CA, DEMARTINO GN: Purification and characterization of a protein inhibitor of the 20S proteasome (macropain). Biochim. Biophys. Acta (1992) 1119:303-311.
41. SCHMID HP, AKHAYAT O, MARTINS DE SA C et al.: The prosome: an ubiquitous morphologically distinct RNP particle associated with repressed mRNPs and containing specific ScRNA and a characteristic set of proteins. EMBO J. (1984) 3:29-34.
42. SCHERRER K: Prosomes, subcomplexes of untranslated mRNP. Mol. Biol. Rep. (1990) 14:1-9.
43. ARRIGO AP, TANAKA K, GOLDBERG AL, WELCH WJ: Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature (1988) 331:192-194. (Pubitemid 18042153)
44. PAMNANI V, HAAS B, PUHLER G, SANGER HL, BAUMEISTER W: Proteasome-associated RNAs are non-specific. Eur. J. Biochem. (1994) 225:511-519. (Pubitemid 24325567)
45. PETIT F, JARROUSSE AS, DAHLMANN B et al.: Involvement of proteasomal subunits zeta and iota in RNA degradation. Biochem. J. (1997) 326:93-98. (Pubitemid 27386922)
46. PETIT F, JARROUSSE AS, BOISSONNET G et al.: Proteasome (prosome) associated endonuclease activity. Mol. Biol. Rep. (1997) 24:113-117. (Pubitemid 27269436)
47. NOTHWANG HG, COUX O, KEITH G, SILVA-PEREIRA I, SCHERRER K: The major RNA in prosomes of HeLa cells and duck erythroblasts is tRNA(Lys,3). Nucleic Acids Res. (1992) 20:1959-1965.
48. JARROUSSE AS, PETIT F, KREUTZER-SCHMID C, GAEDIGK R, SCHMID HP: Possible involvement of proteasomes (prosomes) in AUUUA-mediated mRNA decay. J. Biol. Chem. (1999) 274:5925-5930. (Pubitemid 29109251)
49. OMURA S, FUJIMOTO T, OTOGURO K et al.: Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibiot. (1991) 44:113-116.
50. FENTEANY G, STANDAERT RF, LANE WS et al.: Inhibition of proteasome activities and subunit-specific aminoterminal threonine modification by lactacystin. Science (1995) 268:726-731.
51. SEEMULLER E, LUPAS A, STOCK D et al.: Proteasome from Thermoplasma acidophilum: a threonine protease. Science (1995) 268:579-582.
52. ARENDT CS, HOCHSTRASSER M: Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc. Natl. Acad. Sci. USA (1997) 94:7156-7161. (Pubitemid 27345284)
53. LEE DH, GOLDBERG AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. (1998) 8:397-403. (Pubitemid 28458705)
54. WÓJCIK C: Inhibition of the proteasome as a therapeutic approach. Drug Discov. Today (1999) 4:188-192.
55. ORLOWSKI M: The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry (1990) 29:10289-10297. (Pubitemid 20384536)
56. FIGUEIREDO-PEREIRA ME, BERG KA, WILK S: A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem. (1994) 63:1578-1581.
57. SPALTENSTEIN A, LEBAN JJ, HUANG JJ et al.: Design and synthesis of novel protease inhibitors. Tripeptide a¢,b¢-epoxyketones as nanomolar inactivators of the proteasome. Tetrahedron Lett. (1996) 37:1343-1346.
58. IQBAL M, CHATTERJEE S, KAUER JC et al.: Potent inhibitors of proteasome. J. Med. Chem. (1995) 38:2276-2277.
59. LUM RT, KERWAR SS, MEYER SM et al.: A new class of proteasome inhibitors that prevent NFkB activation. Biochem. Pharmacol. (1998) 55:1391-1397. (Pubitemid 28298519)
60. BOGYO M, SHIN S, MCMASTER JS, PLOEGH HL: Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. (1998) 5:307-320. (Pubitemid 28309984)
61. ADAMS J, BEHNKE M, CHEN S et al.: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. (1998) 8:333-338. (Pubitemid 28072702)
62. LOIDL G, GROLL M, MUSIOL HJ et al.: Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem. Biol. (1999) 6:197-204. (Pubitemid 29368408)
63. MENG L, MOHAN R, KWOK BH et al.: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl. Acad. Sci. USA (1999) 96:10403-10408. (Pubitemid 29422570)
64. SIN N, KIM KB, ELOFSSON M et al.: Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg. Med. Chem. Lett. (1999) 9:2283-2288. (Pubitemid 29371952)
65. MENG L, KWOK BH, SIN N, CREWS CM: Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. (1999) 59:2798-2801. (Pubitemid 29283111)
66. KROLL M, ARENZANA-SEISDEDOS F, BACHELERIE F et al.: The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem. Biol. (1999) 6:689-698. (Pubitemid 29485531)
67. LOIDL G, GROLL M, MUSIOL HJ, HUBER R, MORODER L: Bivalency as a principle for proteasome inhibition. Proc. Natl. Acad. Sci. USA (1999) 96:5418-5422. (Pubitemid 29234632)
68. ISOE T, NAITO M, SHIRAI A, HIRAI R, TSURUO T: Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. Biochim. Biophys. Acta (1992) 1117:131-135.
69. ISOE T, NAITO M, HIRAI R, TSURUO T: Inhibition of ubiquitin-ATP-dependent proteolysis and ubiquitination by cisplatin. AntiCancer Res. (1991) 11:1905-1909.
70. FIGUEIREDO-PEREIRA ME, CHEN WE, LI J, JOHDO O: The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J. Biol. Chem. (1996) 271:16455-16459. (Pubitemid 26238994)
71. KIYOMIYA K, MATSUO S, KUREBE M: Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci. (1998) 62:1853-1860. (Pubitemid 28206670)
72. WILK S, CHEN WE: Synthetic peptide-based activators of the proteasome. Mol. Biol. Rep. (1997) 24:119-124. (Pubitemid 27269437)
73. WILK S, CHEN WE, MAGNUSSON RP: Modulation of the PA28alpha-20S proteasome interaction by a peptidyl alcohol. Arch. Biochem. Biophys. (1999) 362:283-290. (Pubitemid 29394357)
74. OBIN M, MESCO E, GONG X et al.: Neurite outgrowth in PC12 cells. Distinguishing the roles of ubiquitylation and ubiquitin-dependent proteolysis. J. Biol. Chem. (1999) 274:11789-11795.
75. SONODA H, OMI K, HOJO K et al.: Suppression of oncogenic transformation by hypothemycin associated with accelerated cyclin D1 degradation through ubiquitin-proteasome pathway. Life Sci. (1999) 65:381-394. (Pubitemid 29325281)
76. WANG X, OMURA S, SZWEDA LI et al.: Rapamycin inhibits proteasome activator expression and proteasome activity. Eur. J. Immunol. (1997) 27:2781-2786. (Pubitemid 27478343)
77. VASILEVSKAYA IA, PJ OD: Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res. (1999) 59:3935-3940. (Pubitemid 29393557)
78. ADAMS J, STEIN R: Novel inhibitors of the proteasome and their therapeutic use in inflammation. Ann. Rep. Med. Chem. (1996) 31:279-288.
79. PALOMBELLA VJ, RANDO OJ, GOLDBERG AL, MANIATIS T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 78:773-785. (Pubitemid 24294453)
80. ORIAN A, WHITESIDE S, ISRAEL A et al.: Ubiquitinmediated processing of NF-kappa B transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation. J. Biol. Chem. (1995) 270:21707-21714.
81. LIN L, GHOSH S: A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol. Cell. Biol. (1996) 16:2248-2254. (Pubitemid 26123745)
82. ORIAN A, SCHWARTZ AL, ISRAEL A et al.: Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycinerich region and a downstream ubiquitination domain. Mol. Cell. Biol. (1999) 19:3664-3673. (Pubitemid 29193826)
83. TRAENCKNER EB, PAHL HL, HENKEL T et al.: Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBOJ. (1995) 14:2876-2883.
84. TRAENCKNER EB, WILK S, BAEUERLE PA: A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. (1994) 13:5433-5441. (Pubitemid 24351822)
85. CONNER EM, BRAND S, DAVIS JM et al.: Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J. Pharm. Exp. Therap. (1997) 282:1615-1622. (Pubitemid 27408348)
86. PALOMBELLA VJ, CONNER EM, FUSELER JW et al.: Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA (1998) 95:15671-15676. (Pubitemid 29018758)
87. BRAND SJ, MORISE Z, TAGERUD S et al.: Role of the proteasome in rat indomethacin-induced gastropathy [see comments]. Gastroenterology (1999) 116:865-873. (Pubitemid 29153534)
88. ELLIOTT PJ, PIEN CS, MCCORMACK TA, CHAPMAN ID, ADAMS J: Proteasome inhibition: a novel mechanism to combat asthma. J. Allergy Clin. Immunol. (1999) 104:294-300. (Pubitemid 29420423)
89. LUPAS A, ZUHL F, TAMURA T et al.: Eubacterial proteasomes. Molec. Biol. Rep. (1997) 24:125-131. (Pubitemid 27269438)
90. NAGY I, TAMURA T, VANDERLEYDEN J, BAUMEISTER W, DE MOT R: The 20S proteasome of Streptomyces coelicolor. J. Bacteriol. (1998) 180:5448-5453. (Pubitemid 28471544)
91. DE MOT R, NAGY I, WALZ J, BAUMEISTER W: Proteasomes and other self-compartmentalizing proteases in prokaryotes. Trends Microbiol. (1999) 7:88-92. (Pubitemid 29273941)
92. CHUANG SE, BURLAND V, PLUNKETT GD, DANIELS DL, BLATTNER FR: Sequence analysis of four new heat-shock genes constituting the hslTS/ibpAB and hslVU operons in Escherichia coli. Gene (1993) 134:1-6.
93. ROHRWILD M, COUX O, HUANG HC et al.: HslV-HslU: A novel ATP-dependent protease complex in Escherichia coli related to the eukaryotic proteasome. Proc. Natl. Acad. Sci. USA (1996) 93:5808-5813.
94. LEVITSKAYA J , SHARIPO A, LEONCHIKS A, CIECHANOVER A, MASUCCI MG: Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA (1997) 94:12616-12621. (Pubitemid 27492577)
95. GILBERT MJ, RIDDELL SR, PLACHTER B, GREENBERG PD: Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature (1996) 383:720-722. (Pubitemid 26360648)
96. MILLER DM, SEDMAK DD: Viral effects on antigen processing. Curr. Opin. Immunol. (1999) 11:94-99. (Pubitemid 29082344)
97. SAMANIEGO LA, NEIDERHISER L, DELUCA NA: Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. (1998) 72:3307-3320. (Pubitemid 28175576)
98. EVERETT RD: A surprising role for the proteasome in the regulation of herpesvirus infection. Trends Biochem. Sci. (1999) 24:293-295. (Pubitemid 29366800)
99. EVERETT RD, FREEMONT P, SAITOH H et al.: The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110-and proteasomedependent loss of several PML isoforms. J. Virol. (1998) 72:6581-6591. (Pubitemid 28323974)
100. CHELBI-ALIX MK, DE THE H: Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene (1999) 18:935-941. (Pubitemid 29086270)
101. EVERETT RD, ORR A, PRESTON CM: A viral activator of gene expression functions via the ubiquitinproteasome pathway. EMBO J. (1998) 17:7161-7169. (Pubitemid 29002685)
102. ISHOV AM, STENBERG RM, MAUL GG: Human cytomegalovirus immediate early interaction with host nuclear structures: definition of an immediate transcript environment. J. Cell Biol. (1997) 138:5-16. (Pubitemid 27337448)
103. DOUCAS V, ISHOV AM, ROMO A et al.: Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. (1996) 10:196-207. (Pubitemid 26044607)
104. EMERMAN M, MALIM MH: HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science (1998) 5371:1880-1884. (Pubitemid 28299384)
105. SCHUBERT U, ANTON LC, BACIK I et al.: CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. (1998) 3:2280-2288. (Pubitemid 28100787)
106. MARGOTTIN F, BOUR SP, DURAND H et al.: A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell (1998) 4:565-574. (Pubitemid 128374692)
107. DIECKMANN T, WITHERS-WARD ES, JAROSINSKI MA, LIU CF, CHEN IS, FEIGON J: Structure of a human DNA repair protein UBA domain that interacts with HIV-1 Vpr. Nature Struct. Biol. (1998) 12:1042-1047. (Pubitemid 28546266)
108. JARROUSSE AS, GAUTIER K, APCHER S et al.: Relationships between proteasomes and viral gene products. Mol. Biol. Rep. (1999) 1-2:113-117. (Pubitemid 29223260)
109. NAKAMURA T, TANAKA T, NAGANO T, YONEDA T, TAKAGI H, SATO M: Distribution of mRNA encoding Tat-binding protein-1 (TBP-1), a component of 26S proteasome, in the rat brain. Brain Res. Mol. Brain Res. (1998) 1-2:321-327. (Pubitemid 28085471)
110. SEEGER M, FERRELL K, FRANK R, DUBIEL W: HIV-1 tat inhibits the 20 S proteasome and its 11 S regulatormediated activation. J. Biol. Chem. (1997) 13:8145-8148. (Pubitemid 27147763)
111. ROSSI F, EVSTAFIEVA A, PEDRALI-NOY G, GALLINA A, MILANESI. G: HsN3 proteasomal subunit as a target for human immunodeficiency virus type 1 Nef protein. Virology (1997) 1:33-45. (Pubitemid 27464838)
112. SCHWARTZ O, MARECHAL V, FRIGUET B, ARENZANASEISDEDOS F, HEARD JM: Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J. Virol. (1998) 5:3845-3850. (Pubitemid 28188684)
113. TANG G, LEPPLA SH: Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect. Immun. (1999) 67:3055-3060. (Pubitemid 29244729)
114. MAKSYMOWYCH WP, IKAWA T, YAMAGUCHI A et al.: Invasion by Salmonella typhimurium induces increased expression of the LMP, MECL, and PA28 proteasome genes and changes in the peptide repertoire of HLA-B27. Infect. Immun. (1998) 66:4624-4632. (Pubitemid 28453061)
115. GANTT SM, MYUNG JM, BRIONES MR et al.: Proteasome inhibitors block development of Plasmodium spp. Antimicrob. Agents Chemother. (1998) 42:2731-2738. (Pubitemid 28462924)
116. GONZALEZ J, RAMALHO-PINTO FJ, FREVERT U et al.: Proteasome activity is required for the stage-specific transformation of a protozoan parasite. J. Exp. Med. (1996) 184:1909-1918. (Pubitemid 26404481)
117. MUTOMBA MC, TO WY, HYUN WC, WANG CC: Inhibition of proteasome activity blocks cell cycle progression at specific phase boundaries in African trypanosomes. Molec. Biochem. Parasitol. (1997) 90:491-504. (Pubitemid 28039804)
118. GONZALEZ J, BAI G, FREVERT U, COREY EJ, EICHINGER D: Proteasome-dependent cyst formation and stagespecific ubiquitin mRNA accumulation in Entamoeba invadens. Eur. J. Biochem. (1999) 264:897-904. (Pubitemid 29437221)
119. FEATHERSTONE C: Proteasome inhibitors in development for malaria [news]. Molec. Med. Today (1997) 3:367.
120. TAKAOKA M, OKAMOTO H, ITO M et al.: Antihypertensive effect of a proteasome inhibitor in DOCA-salt hypertensive rats. Life Sci. (1998) 63:PL65-70. (Pubitemid 28302475)
121. STAUB O, GAUTSCHI I, ISHIKAWA T et al.: Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBOJ. (1997) 16:6325-6336. (Pubitemid 27483259)
122. LOWE J, BLANCHARD A, MORRELL K et al.: Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J. Pathol. (1988) 155:9-15.
123. LENNOX G, LOWE J, MORRELL K, LANDON M, MAYER RJ: Ubiquitin is a component of neurofibrillary tangles in a variety of neurodegenerative diseases. Neurosci. Lett. (1988) 94:211-217.
124. KUZUHARA S, MORI H, IZUMIYAMA N, YOSHIMURA M, IHARA Y: Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. (1988) 75:345-353. (Pubitemid 18070910)
125. LEIGH PN, ANDERTON BH, DODSON A et al.: Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci. Lett. (1988) 93:197-203.
126. SUENAGA T, HIRANO A, LLENA JF et al.: Ubiquitin immunoreactivity in kuru plaques in Creutzfeldt-Jakob disease. Ann. Neurol. (1990) 28:174-177. (Pubitemid 20244519)
127. PERRY G, FRIEDMAN R, SHAW G, CHAU V: Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer's disease brains. Proc. Natl. Acad. Sci. USA (1987) 84:3033-3036. (Pubitemid 17064772)
128. COLE GM, TIMIRAS PS: Ubiquitin-protein conjugates in Alzheimer's lesions. Neurosci. Lett. (1987) 79:207-212. (Pubitemid 17144471)
129. MORI H, KONDO J, IHARA Y: Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science (1987) 235:1641-1644. (Pubitemid 17050146)
130. LOWE J, MAYER RJ, LANDON M: Ubiquitin in neurodegenerative diseases. Brain Pathol. (1993) 3:55-65. (Pubitemid 23046376)
131. II K, ITO H, TANAKA K, HIRANO A: Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. (1997) 56:125-131. (Pubitemid 27461174)
132. MORANDI A, LOS B, OSOFSKY L, AUTILIO-GAMBETTI L, GAMBETTI P: Ubiquitin and heat shock proteins in cultured nervous tissue after different stress conditions. Prog. Clin. Biol. Res. (1989) 317:819-827.
133. WOJCIK C, SCHROETER D, WILK S, LAMPRECHT J, PAWELETZ N: Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome. Eur. J. Cell Biol. (1996) 71:311-318. (Pubitemid 26388427)
134. JOHNSTON JA, WARD CL, KOPITO RR: Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. (1998) 143:1883-1898. (Pubitemid 29022611)
135. FIGUEIREDO-PEREIRA ME, COHEN G: The ubiquitin/proteasome pathway: friend or foe in zinc-, cadmium-, and H2O2-induced neuronal oxidative stress. Mol. Biol. Rep. (1999) 26:65-69. (Pubitemid 29223253)
136. GARCIA-MATA R, BEBOK Z, SORSCHER EJ, SZTUL ES: Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. (1999) 146:1239-1254. (Pubitemid 29477692)
137. NOTTERPEK L, RYAN MC, TOBLER AR, SHOOTER EM: PMP22 Accumulation in aggresomes: implications for CMT1A pathology. Neurobiol. Dis. (1999) 6:450-460. (Pubitemid 29496222)
138. MCKEON-O'MALLEY C, SAUNDERS AJ, BUSH AI, TANZI RE: Potential therapeutic targets for Alzheimer's disease. Emerging Therapeutic Targets (1998) 2:157-179.
139. GLENNER GG, WONG CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. (1984) 120:885-890. (Pubitemid 14104991)
140. ISHIURA S, TSUKAHARA T, TABIRA T, SUGITA H: Putative N-terminal splitting enzyme of amyloid A4 peptides is the multicatalytic proteinase, ingensin, which is widely distributed in mammalian cells. FEBS Lett. (1989) 257:388-392.
141. KOJIMA S, OMORI M: Two-way cleavage of beta-amyloid protein precursor by multicatalytic proteinase. FEBS Lett. (1992) 304:57-60.
142. MARAMBAUD P, CHEVALLIER N, BARELLI H, WILK S, CHECLER F: Proteasome contributes to the alphasecretase pathway of amyloid precursor protein in human cells. J. Neurochem. (1997) 68:698-703. (Pubitemid 27044732)
143. HIGAKI J, QUON D, ZHONG Z, CORDELL B: Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron (1995) 14:651-659.
144. ALLSOP D, CHRISTIE G, GRAY C et al.: Studies on inhibition of b-amyloid formation in APP751-transfected IMR-32 cells and SPA4CT-transfected SHSY5Y cells. In: Alzheimer's Disease: Biology, Diagnostics and Therapeutics. Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (Eds.), John Wiley, New York, USA (1997):717-727.
145. KLAFKI H, ABRAMOWSKI D, SWOBODA R, PAGANETTI PA, STAUFENBIEL M: The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J. Biol. Chem. (1996) 271:28655-28659. (Pubitemid 26374693)
146. KLAFKI HW, PAGANETTI PA, SOMMER B, STAUFENBIEL M: Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta-amyloid precursor protein carrying the APP670/671 double mutation. Neurosci. Lett. (1995) 201:29-32.
147. CHRISTIE G, MARKWELL RE, GRAY CWet al.: Alzheimer's disease: correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome. J. Neurochem. (1999) 73:195-204. (Pubitemid 29289127)
148. GREGORI L, FUCHS C, FIGUEIREDO-PEREIRA ME, VAN NOSTRAND WE, GOLDGABER D: Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. (1995) 270:19702-19708.
149. ALZHEIMER'S DISEASE COLLABORATIVE GROUP: The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genet. (1995) 11:219-222.
150. LEVY-LAHAD E, WIJSMAN EM, NEMENS E et al.: A familial Alzheimer's disease locus on chromosome 1 [see comments]. Science (1995) 269:970-973.
151. STEINER H, CAPELL A, PESOLD B et al.: Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. (1998) 273:32322-32331. (Pubitemid 29177180)
152. HONDA T, YASUTAKE K, NIHONMATSU N et al.: Dual roles of proteasome in the metabolism of presenilin 1. Am. J. Physiol. (1999) 276:L9-L19.
153. MARAMBAUD P, ANCOLIO K, LOPEZ-PEREZ E, CHECLER F: Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells. Molec. Med. (1998) 4:147-157. (Pubitemid 28223966)
154. ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer. Res. (1999) 59:2615-2622. (Pubitemid 29269108)
155. FENTEANY G, SCHREIBER SL: Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. Chem. Biol. (1996) 3:905-912. (Pubitemid 27017089)
156. WILK S, CHEN WE, MAGNUSSON RP: Modulators of the activation of the proteasome by PA28 (11S reg). Mol. Biol. Rep. (1999) 26:39-44. (Pubitemid 29223249)
157. ATTAIX D, AUROUSSEAU E, COMBARET L et al.: Ubiquitin-proteasome dependent proteolysis in skeletal muscle. Reprod. Nutr. Dev. (1998) 38:153-165. (Pubitemid 28241308)
158. FURUNO K, GOODMAN MN, GOLDBERG AL: Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy. J. Biol. Chem. (1990) 265:8550-8557.
159. MYKLES DL: Lobster muscle proteasome and the degradation of myofibrillar proteins. Enzyme Protein (1993) 47:220-231.
160. EBLE DM, SPRAGIA ML, FERGUSON AG, SAMAREL AM: Sarcomeric myosin heavy chain is degraded by the proteasome. Cell Tissue Res. (1999) 296:541-548. (Pubitemid 29253685)
161. MITCH WE, GOLDBERG AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. New Engl. J. Med. (1996) 335:1897-1905. (Pubitemid 26419198)
162. HASSELGREN PO: Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care (1999) 2:201-205.
163. GRIZARD J, DARDEVET D, BALAGE M et al.: Insulin action on skeletal muscle protein metabolism during catabolic states. Reprod. Nutr. Dev. (1999) 39:61-74. (Pubitemid 129591411)
164. TAWA NE, JR., ODESSEY R, GOLDBERG AL: Inhibitors of the proteasome reduce
165. LECKER SH, SOLOMON V, MITCH WE, GOLDBERG AL: Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J. Nutr. (1999) 129:243S-246S.
166. COMBARET L, RALLIERE C, TAILLANDIER D, TANAKA K, ATTAIX D: Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Mol. Biol. Rep. (1999) 26:95-101. (Pubitemid 29223258)
167. LAZARUS DD, DESTREE AT, MAZZOLA LM et al.: A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am. J. Physiol. (1999) 277:E332-E341. (Pubitemid 29413840)
168. HOBLER SC, TIAO G, FISCHER JE, MONACO J, HASSELGREN PO: Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. Am. J. Physiol. (1998) 274:R30-R37.
169. ATTAIX D, COMBARET L, TILIGNAC T, TAILLANDIER D: Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia. Mol. Biol. Rep. (1999) 26:77-82. (Pubitemid 29223255)
170. COMBARET L, TAILLANDIER D, VOISIN L et al.: No alteration in gene expression of components of the ubiquitin-proteasome proteolytic pathway in dystrophin-deficient muscles. FEBS Lett. (1996) 393:292-296. (Pubitemid 26298113)
171. GLOTZER M, MURRAY AW, KIRSCHNER MW: Cyclin is degraded by the ubiquitin pathway. Nature (1991) 349:132-138. (Pubitemid 21912025)
172. ROLFE M, CHIU MI, PAGANO M: The ubiquitin-mediated proteolytic pathway as a therapeutic area. J. Molec. Med. (1997) 75:5-17. (Pubitemid 27067134)
173. HERSHKO A: Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr. Opin. Cell Biol. (1997) 9:788-799. (Pubitemid 27517267)
174. ELLEDGE SJ, HARPER JW: The role of protein stability in the cell cycle and cancer. Biochim. Biophys. Acta (1998) 1377:M61-M70. (Pubitemid 28207049)
175. WADA M, KOSAKA M, SAITO S et al.: Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance [see comments]. J. Lab. Clin. Med. (1993) 121:215-223. (Pubitemid 23073128)
176. DIETRICH C, BARTSCH T, SCHANZ F, OESCH F, WIESER RJ: p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl. Acad. Sci. USA (1996) 93:10815-10819.
177. WOJCIK C, SCHROETER D, STOEHR M, WILK S, PAWELETZ N: An inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces arrest in G2-phase and metaphase in HeLa cells. Eur. J. Cell Biol. (1996) 70:172-178. (Pubitemid 26177217)
178. IMAJOH-OHMI S, KAWAGUCHI T, SUGIYAMA S et al.: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Comm. (1995) 217:1070-1077.
179. WOJCIK C, STOKLOSA T, GIERMASZ A et al.: Apoptosis induced in L1210 leukemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis (1997) 2:455-462. (Pubitemid 127508256)
180. SADOUL R, FERNANDEZ PA, QUIQUEREZ AL et al.: Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. (1996) 15:3845-3852. (Pubitemid 26289794)
181. GRIMM LM, GOLDBERG AL, POIRIER GG, SCHWARTZ LM, OSBORNE BA: Proteasomes play an essential role in thymocyte apoptosis. EMBO J. (1996) 15:3835-3844. (Pubitemid 26289793)
182. WOJCIK C, MLYNARCZUK I, HOSER G et al.: A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias is potentially dangerous [letter]. Blood (1999) 94:1827-1828. (Pubitemid 29411336)
183. LIN KI, BARABAN JM, RATAN RR: Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ. (1998) 5:577-583. (Pubitemid 28356579)
184. GRIMM LM, OSBORNE BA: Apoptosis and the proteasome. Results Probl. Cell. Differ. (1999) 23:209-228.
185. ORLOWSKI RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. (1999) 6:303-313. (Pubitemid 29186874)
186. DELIC J, MASDEHORS P, OMURA S et al.: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br. J. Canc. (1998) 77:1103-1107. (Pubitemid 28116281)
187. OIKAWA T, SASAKI T, NAKAMURA M et al.: The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. (1998) 246:243-248. (Pubitemid 28413959)
188. STOKLOSA T, GOLAB J, WÓJCIK C et al.: Antitumor effect of proteasome inhibitor dependent on p53 induction and angiogenesis inhibition. Third Workshop on Proteasomes. (1999) Clermont-Ferrand, France.
189. OIKAWA T, HASEGAWA M, SHIMAMURA M et al.: Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor. Biochem. Biophys. Res. Commun. (1991) 181:1070-1076.
190. ORLOWSKI RZ, ESWARA JR, LAFOND-WALKER A et al.: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. (1998) 58:4342-4348. (Pubitemid 28450035)
191. HANADA M, SUGAWARA K, KANETA K et al.: Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. (1992) 45:1746-1752. (Pubitemid 23015454)
192. SUGAWARA K, HATORI M, NISHIYAMA Y et al.: Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. J. Antibiot. (1990) 43:8-18. (Pubitemid 20043960)
193. TEICHER BA, ARA G, HERBST R, PALOMBELLA VJ, ADAMS J: The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. (1999) 5:2638-2645. (Pubitemid 29437352)
194. SPATARO V, NORBURY C, HARRIS AL: The ubiquitinproteasome pathway in cancer. Br. J. Canc. (1998) 77:448-455.
195. RAY K, HARRIS H: Purification of neutral lens endopeptidase: close similarity to a neutral proteinase in pituitary. Proc. Natl. Acad. Sci. USA (1985) 82:7545-7549. (Pubitemid 16204384)
196. TAYLOR A, DAVIES KJ: Protein oxidation and loss of protease activity may lead to cataract formation in the aged lens. Free Radic. Biol. Med. (1987) 3:371-377. (Pubitemid 18017384)
197. MURAKAMI K, JAHNGEN JH, LIN SW, DAVIES KJ, TAYLOR A: Lens proteasome shows enhanced rates of degradation of hydroxyl radical modified alpha-crystallin. Free Radic. Biol. Med. (1990) 8:217-222.
198. SHANG F, GONG X, PALMER HJ, NOWELL TR, JR., TAYLOR A: Age-related decline in ubiquitin conjugation in response to oxidative stress in the lens. Exp. Eye Res. (1997) 64:21-30. (Pubitemid 27096636)
199. ANDERSSON M, SJOSTRAND J, KARLSSON J: Proteolytic cleavage of N-Succ-Leu-Leu-Val-Tyr-AMC by the proteasome in lens epithelium from clear and cataractous human lenses. Exp. Eye Res. (1998) 67:231-236. (Pubitemid 28428271)
200. WARD CL, OMURA S, KOPITO RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell (1995) 83:121-127.
201. XIONG X, CHONG E, SKACH WR: Evidence that endoplasmic reticulum (ER)-associated degradation of cystic fibrosis transmembrane conductance regulator is linked to retrograde translocation from the ER membrane. J. Nutr. (1999) 129:227S-237S.
202. KOPITO RR: Biosynthesis and degradation of CFTR. Physiol. Rev. (1999) 79:S167-S173. (Pubitemid 29058913)
203. WIGLEY WC, FABUNMI RP, LEE MG et al.: Dynamic association of proteasomal machinery with the centrosome. J. Cell Biol. (1999) 145:481-490. (Pubitemid 29215713)
204. SUTCLIFFE JS, JIANG YH, GALIJAARD RJ et al.: The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region [letter]. Genome Res. (1997) 7:368-377. (Pubitemid 27183005)
205. FANG P, LEV-LEHMAN E, TSAI TF et al.: The spectrum of mutations in UBE3A causing Angelman syndrome. Hum. Molec. Genet. (1999) 8:129-135. (Pubitemid 29039058)
206. ALBRECHT U, SUTCLIFFE JS, CATTANACH BM et al.: Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nature Genet. (1997) 17:75-78. (Pubitemid 27377535)
207. ROEST HP, VAN KLAVEREN J, DE WIT J et al.: Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification. Cell (1996) 86:799-810.4 .
208. BAARENDS WM, ROEST HP, GROOTEGOED JA: The ubiquitin system in gametogenesis. Mol. Cell Endocrinol. (1999) 151:5-16.
209. PERRY WL, HUSTAD CM, SWING DAet al.: The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice [see comments]. Nature Genet. (1998) 18:143-146. (Pubitemid 28082460)
210. ARRIBAS J, LUZ RODRIGUEZ M, ALVAREZ-DO FORNO R, CASTANO JG: Autoantibodies against the multicatalytic proteinase in patients with systemic lupus erythematosus. J. Exp. Med. (1991) 173:423-427.
211. FEIST E, DORNER T, KUCKELKORN U et al.: Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J. Exp. Med. (1996) 184:1313-1318. (Pubitemid 26354687)